Home  »  Stocks to Invest   »  Poseida Therapeutics Inc. (PSTX) Stock on the Rise...

Poseida Therapeutics Inc. (PSTX) Stock on the Rise Following Exclusive License Agreement with Takeda

Poseida Therapeutics Inc. (PSTX) stock prices were up by 1.22% as of the market closing on October 11th, 2021. This brought the price per share up to USD$6.65 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 7.37%, bringing it down to USD$7.14.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Partnership with Takeda

October 12th, 2021 saw PSTX stock announce having entered into a research and collaboration and exclusive license agreement with Takeda. The collaboration with Takeda Pharmaceutical Company Ltd. will utilize the company’s piggyback, Cas-CLOVER, biodegradable DNA, and RNA nanoparticle delivery technology. In conjunction with other proprietary genetic engineering platforms for the research and development of up to eight gene therapies. The partnership will focus on developing non-viral in vivo gene therapy programs, including the company’s Hemophilia A program.

Details of the Collaboration

The partnership with the global biopharmaceutical leader will complement the company’s innovative platform technologies and robust gene therapy pipeline. The company’s technologies offer highly efficient gene delivery, fully integrated non-viral genome insertion, and ultra-precise site-specific gene editing. The partnering companies hope to develop potential cures for a number of genetic diseases with high unmet need. As per the agreement, the partners will work to initially develop up to six in vivo gene therapy programs that will utilize PSTX stock’s novel technology platforms, as well as certain emerging technologies. these platforms include its piggyBac, Cas-CLOVER, and biodegradable nanoparticle technology. The partnering company has included an option to add two addition programs to the collaboration and will be obligated to provide funding for all the R&D costs of the collaboration program.

PSTC Stock’s Lucrative Collaboration

PSTX stock is set to receive an upfront payment of USD$45 million. If milestones for six programs are achieved, the company can also expect additional payments that have the potential to exceed and aggregate of USD$125 million. The company is also eligible to receive future clinical development, regulatory, and commercial milestone payments. The total potential value of the course of the partnership could reach USD$2.7 billion, should the milestones for all six programs are achieved. Achieving milestones for the additional two programs would bring the potential total up to USD$3.6 billion.

Future Outlook for PSTX Stock

The company is keen to capitalize on the expanded scope of opportunities afford to it as a result of its partnership with Takeda. PSTX stock is keen to facilitate the development of all of the combined programs that are a part of the collaboration. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal effectively. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts